# Efficacy and Safety of Rifaximin in Treating MAFLD

> **NCT07185932** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Metabolic-associated Fatty Liver Disease

## Interventions

- **DRUG:** Rifaximin (Xifaxan)

## Key facts

- **NCT ID:** NCT07185932
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185932, "Efficacy and Safety of Rifaximin in Treating MAFLD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07185932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*